Evidence map›Paper›PMID 38883392›Full record

ArticleAmerican journal of translational research2024

Exploring the neuropharmacological properties of scopoletin-rich

Shamshad Ather, Chayan Bhattacharyya, Himanshu Gupta, Yogesh Patil, Sairam Reddy Palicherla, Gauri Patil, Yasmin Khatoon, Pramodkumar P Gupta, Kapil Singh Thakur, Mansee Thakur

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shamshad AtherDepartment of Medical Biotechnology, Central Research Laboratory, Mahatma Gandhi Mission, School of Biomedical Sciences, Mahatma Gandhi Mission Institute of Health Sciences Navi Mumbai 410209, Maharashtra, India.
Chayan BhattacharyyaDepartment of Medical Biotechnology, Central Research Laboratory, Mahatma Gandhi Mission, School of Biomedical Sciences, Mahatma Gandhi Mission Institute of Health Sciences Navi Mumbai 410209, Maharashtra, India.
Himanshu GuptaDepartment of Medical Biotechnology, Central Research Laboratory, Mahatma Gandhi Mission, School of Biomedical Sciences, Mahatma Gandhi Mission Institute of Health Sciences Navi Mumbai 410209, Maharashtra, India.
Yogesh PatilDepartment of Medical Biotechnology, Central Research Laboratory, Mahatma Gandhi Mission, School of Biomedical Sciences, Mahatma Gandhi Mission Institute of Health Sciences Navi Mumbai 410209, Maharashtra, India.
Sairam Reddy PalicherlaHeartfulness Institute Kanha Shanti Vanam, Kanha Village, Nandigama Mandal, Rangareddy District, Hyderabad 509325, Telangana, India.
Gauri PatilDepartment of Medical Biotechnology, Central Research Laboratory, Mahatma Gandhi Mission, School of Biomedical Sciences, Mahatma Gandhi Mission Institute of Health Sciences Navi Mumbai 410209, Maharashtra, India.
Yasmin KhatoonDepartment of Medical Biotechnology, Central Research Laboratory, Mahatma Gandhi Mission, School of Biomedical Sciences, Mahatma Gandhi Mission Institute of Health Sciences Navi Mumbai 410209, Maharashtra, India.
Pramodkumar P GuptaDepartment of Bioinformatics, DY Patil College School of Biotechnology and Bioinformatics Belapur, Navi Mumbai 400614, Maharashtra, India.
Kapil Singh ThakurNuvox Healthcare Pvt. Ltd. Hiranandani Gardens, Powai, Mumbai 400076, Maharashtra, India.
Mansee ThakurDepartment of Medical Biotechnology, Central Research Laboratory, Mahatma Gandhi Mission, School of Biomedical Sciences, Mahatma Gandhi Mission Institute of Health Sciences Navi Mumbai 410209, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study investigates the neuropharmacologic properties of Scopoletin, a bioactive compound in

methodsThe study estimates Scopoletin concentration in EA extract using HPTLC, assesses antioxidant properties using 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and ferric reducing ability of plasma (FRAP) assays, and uses bioinformatic tools for scopoletin targets. Zebrafish embryo toxicity (ZET) is used to assess its toxicological profile.

results0.0076% w/w Scopoletin in the samples was quantified using HPTLC, further studies on the DPPH (0.5 mM) and FRAP gave EC

conclusionThe study verifies the presence of Scopoletin in EA, along with their targets playing a crucial role in neurogenesis and neuroplasticity. The ZET demonstrated concentration-dependent effects, emphasizing the importance of dosage considerations in developing new formulations or therapeutics. This comprehensive study contributes valuable insight into the therapeutic potential of Scopoletin from EA for cognitive impairment, paving the way for further research.

Indexed as

cognitive impairmentEvolvulus alsinoidesFETHPTLCin-silicoscopoletin

Identifiers

PMID38883392
PMCPMC11170599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.